Medical Castration Using the Investigational Oral GnRH Antagonist TAK-385 (Relugolix): Phase 1 Study in Healthy Males
Author:
Affiliation:
1. Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (D.B.M., H.S., H.F.), Cambridge, Massachusetts 02139
2. University of Montreal Hospital Center (F.S.), Montreal, Québec, Canada H2X 0A9
Publisher
The Endocrine Society
Subject
Biochemistry, medical,Clinical Biochemistry,Endocrinology,Biochemistry,Endocrinology, Diabetes and Metabolism
Link
http://academic.oup.com/jcem/article-pdf/100/12/4579/10422783/jcem4579.pdf
Reference23 articles.
1. New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists;Shore;Prostate Cancer Prostatic Dis,2013
2. An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer;Rick;Onco Targets Ther,2013
3. Flare associated with LHRH-agonist therapy;Thompson;Rev Urol,2001
4. Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics;Tombal;Eur Urol,2010
5. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer;Klotz;BJU Int,2008
Cited by 50 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Impact of Relugolix Versus Leuprolide on the Quality of Life of Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study;European Urology;2023-12
2. Testosterone Recovery for Relugolix Versus Leuprolide in Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study;European Urology Oncology;2023-12
3. Early biochemical outcomes following neoadjuvant/adjuvant relugolix with stereotactic body radiation therapy for intermediate to high risk prostate cancer;Frontiers in Oncology;2023-10-17
4. Relugolix vs. Leuprolide Effects on Castration Resistance-Free Survival from the Phase 3 HERO Study in Men with Advanced Prostate Cancer;Cancers;2023-10-05
5. Considerations on implementation of the newest treatment for symptomatic uterine fibroids: Oral GnRH antagonists;British Journal of Clinical Pharmacology;2023-09-27
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3